Canine Cognition Assessments in Aging Dogs
Author Information
Author(s): Holland Sydney, Ferguson Anna, Creevy Kate, Anderson Rozalyn, Reed May
Primary Institution: Texas A&M University College of Veterinary Medicine and Biomedical Sciences
Hypothesis
Does rapamycin treatment extend lifespan and impact cognitive function in aging dogs?
Conclusion
The study found no significant correlations between demographic factors and cognitive function in middle-aged dogs.
Supporting Evidence
- The median age of evaluated dogs was 9.2 years.
- The median weight of the dogs was 27.7 kg.
- The median CADES score was 1.0, indicating low cognitive impairment.
- The median Sustained Gaze score was 9.0, indicating a moderate attention span.
Takeaway
Researchers are studying if a drug called rapamycin can help older dogs live longer and think better, but so far, it seems that age, weight, and breed don't affect their thinking skills.
Methodology
This is a placebo-controlled, double-blinded, randomized clinical trial assessing cognitive function in dogs.
Limitations
The study is still ongoing, and only baseline data is available.
Participant Demographics
Dogs included were healthy, middle-aged, medium-to-large companion dogs with a median age of 9.2 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website